Introduction
============

Primary lung cancer remains the leading cause of cancer mortality in China [@B1]. Patients with non-small cell lung cancer (NSCLC) account for \~80% of lung cancer cases, and have a poor 5-year survival rate. NSCLC is characterized by the accumulation [@B2] of multiple genetic alterations [@B3], oncogenic driver mutations, which constitutively activate signaling pathways, leading to uncontrolled cell growth and proliferation. A number of mutations in key oncogenes have been identified as important genetic alterations in lung adenocarcinoma (LAC), including genes encoding epidermal growth factor receptor (*EGFR*), Kirsten rat sarcoma viral oncogene homolog (*KRAS*), and anaplastic lymphoma kinase (*ALK*). These genetic variations provide prognostic value, as well as being specific molecular targets for therapeutic intervention [@B4]-[@B6]. During the past decade, emerging targeted therapies have led to a pattern shift in lung cancer treatment. For instance, tyrosine kinase inhibitors (TKIs) targeting *EGFR* mutations and *ALK* rearrangements have shown significant clinical efficacy in treating patients with advanced NSCLC harboring corresponding mutations [@B7].

EGFR is a 486-amino acid, 170 kDa receptor glycoprotein with a single transmembrane sequence that was first identified as a binding partner of EGF. As a member of the ErbB receptor TK family, EGFR has an extracellular ligand-binding domain, a transmembrane lipophilic segment, and an intracellular domain with TK activity. On binding a growth factor, EGFR is self-phosphorylated by TK, then it activates cell signaling pathways involved in regulation of the cell cycle, apoptosis, angiogenesis, and cellular proliferation. Specific *EGFR* mutations induce constant phosphorylation of EGFR, which activates downstream signals. EGFR dysregulation plays a crucial role in the pathogenesis and progression of NSCLC [@B8], [@B9], and these findings have led to the development of anticancer drugs. In the early 2000s, gefitinib and erlotinib were the first two EGFR TKIs to be investigated as inhibitors of the EGFR signaling pathway. They were studied in previously treated NSCLC patients [@B10], and have proven successful in controling this disease [@B11]-[@B13]. More recently, a randomized, international, open-label, phase 3 trial proved that osimertinib had significantly greater efficacy than platinum therapy plus pemetrexed in patients with T790M-positive advanced NSCLC in whom disease had progressed during first-line EGFR TKI therapy [@B14].

The echinoderm microtubule-associated protein-like 4-anaplastic lymphoma kinase fusion gene (*EML4-ALK*), generally known as the *ALK* fusion gene, was first described in 2007. The fusion results from a small inversion within chromosome 2p, leading to expression of a chimeric TK in which the N-terminal half of EML4 is fused to the intracellular kinase domain of ALK. This then activates protein kinase domains and downstream signaling pathways that are important in tumorigenicity. EML4-ALK possesses powerful oncogenic activity both *in vitro* and *in vivo* [@B15], [@B16], which can be blocked by small-molecule inhibitors that target ALK, supporting a role for EML4-ALK as a key driver of lung tumorigenesis. The overall incidence of the *ALK* fusion gene in patients with LAC is 5.2%-11.2% [@B17], [@B18]. Consequently, it is another important target in the treatment of NSCLC [@B16]. Crizotinib is an ALK-TKI that plays a central role in this context, having been granted approval by the FDA in 2011.

*EGFR* and *ALK* are the two most important driver genes that have been found in 30%-40% and 2%-7% of NSCLC patients, respectively [@B19]-[@B21]; they have a higher prevalence in patients with adenocarcinoma, younger patients, women, Asians, and those who have never smoked. *EGFR* mutations and *ALK* rearrangements are expected to have intrinsic prognostic value for survival because of the favorable clinicopathologic features of tumor types with these mutations. This has been indicated in previous studies of patients with advanced or early NSCLC with *EGFR* mutations [@B5], [@B8], [@B22], and patients with *EGFR* wild-type (WT) lung adenocarcinomas with *ALK* rearrangements[@B23]. However, few reports have specifically evaluated the prognostic difference of *EGFR* mutations and *ALK* rearrangements in surgically resected LAC. Therefore, to clarify the role of these two oncogenic mutations in predicting the outcome of resected LAC, we comprehensively evaluated the prognostic significance of *EGFR* mutations and *ALK* rearrangements on disease-free survival (DFS) and overall survival (OS) in patients with completely resected primary LAC at a single institution.

Materials and methods
=====================

Study population and tumor tissue samples
-----------------------------------------

This study adhered to Reporting Recommendations for Tumor Marker Prognostic Studies guidelines [@B24]. Six hundred and seventy-five consecutive patients with primary LAC who underwent complete surgical resection were enrolled in this retrospective study. All patients were admitted to the Tianjin Medical University Cancer Institute and Hospital (Tianjin, China) between January 2011 and December 2015, and had a pathologically confirmed diagnosis. Patients who did not undergo curative resection or had a previous history of other cancers or had any anticancer therapies before surgery were excluded. None of the patients in the study cohort had received corresponding molecular targeted therapy before tumor recurrence. Patients with comorbidity that might have affected OS, such as advanced cardiovascular disease, were also excluded from the study.

Most of the patients at a locally advanced stage received two to four cycles of platinum-based adjuvant chemotherapy following surgery (platinum- pemetrexed, taxol, or docetaxol). Clinical data were collected from the hospital\'s medical recording system and are described in Table [1](#T1){ref-type="table"}. Tumors were staged pathologically according to the 8th edition of the tumor-node-metastasis (TNM) classification for lung cancer [@B25]. Histologic subtypes were determined according to the 2011 IASLC/ATS/ERS international multidisciplinary classification of LAC [@B26]. The morphology of all samples was reviewed by two experienced pathologists from Tianjin Lung Cancer Center (Z.Z. and Q.Y.) on a blinded basis. Formalin- fixed, paraffin-embedded (FFPE) tumor tissues collected in surgical resection were used. Patients with insufficient or poor-quality tissue for molecular analyses, or inconclusive *ALK* rearrangements, were excluded.

Following tumor resection, the patients were followed up every 3 months during the first 2 years and every 6 to 12 months over the next 3 years. Tumor recurrence was identified using radiological examination or biopsy. In the majority of patients, interval computed tomography scans were available for review by one thoracic radiologist. DFS was measured from the day of tumor resection until tumor recurrence or death. OS, defined as the time from curative operation to death from any cause, is a direct measure of clinical benefit to the patient. Patients alive or lost to follow-up were censored. Patients without a known date of death were censored at the time of last follow-up. Informed consent was received from patients or their families, and this study was approved by the Research Ethics Committee of Tianjin Medical University Cancer Institute and Hospital.

Mutation analysis
-----------------

The detection of *ALK* rearrangements was performed using the fully-automated Ventana immunohistochemistry (IHC) assay on a Benchmark XT autostainer (Ventana Medical Systems, Inc., Tucson, AZ, USA) using monoclonal rabbit anti-human ALK antibody (clone D5F3; catalog no. 790-4794; Ventana Medical Systems, Inc.). The Optiview DAB IHC detection kit (catalog no. 860-099; Ventana Medical Systems, Inc.) was used according to the manufacturer\'s protocols. As previously reported [@B27]-[@B29], positive staining was indicated by strong granular staining in the tumor cell cytoplasm in any percentage of positive tumor cells; otherwise, the expression of ALK was considered to be negative (a binary scoring system). *ALK* rearrangements and histologic subtypes were determined by two experienced pathologists from Tianjin Lung Cancer Center (Z.Z. and Q.Y.) on a blinded basis.

DNA extraction, reverse transcription (RT)-PCR amplification, and direct sequencing were performed for the detection of *EGFR*/*KRAS* mutations. Genomic DNA was extracted from FFPE blocks divided into 10-15 4-µm thick sections. The purified PCR product was analyzed using an ABI 3130xl sequencer. PolyPhred software [@B30] was used to analyze the sequence. To validate RT-PCR results, all samples were assessed by direct DNA sequencing.

Statistical analysis
--------------------

The associations of genotype with clinicopathological characteristics and treatment types were assessed by Fisher\'s exact test for categorical data, and the Wilcoxon rank sum test for continuous data. DFS and OS were plotted using the Kaplan-Meier method, and the difference between genotypes was compared using the log-rank test. The Cox multivariate proportional hazard model was used for multivariate survival analysis, and hazard ratios (HRs) and 95% confidence intervals (CIs) were calculated. All statistical tests were performed using SPSS version 20.0 software (SPSS Inc., Chicago, IL, USA). Values of *P* \< 0.05 for the two-tailed test were considered to indicate a statistically significant difference.

Results
=======

Patient characteristics
-----------------------

A total of 675 patients with LAC (320 males and 355 females) were enrolled in this study, with a median age of 60 years (range, 28-79 years). All patients were diagnosed at various clinical stages according to the latest edition of the TNM Classification for lung cancer: 380 patients at stage I, 73 at stage II, and 222 at stage III. Postoperative adjuvant therapy (chemotherapy, radiotherapy, or biotherapy) was administered to 360 patients. Patient clinicopathologic characteristics are summarized in Table [1](#T1){ref-type="table"}.

Histological features
---------------------

The proportion of histopathologic subtypes, determined according to the 2011 IASLC/ATS/ERS international multidisciplinary classification of LAC [@B26], were invasive adenocarcinoma in 615 patients (91.1%), with lepidic predominant, acinar predominant, papillary predominant, micropapillary predominant, and solid predominant with mucin production subtypes present in 126 (18.7%), 283 (41.9%), 50 (7.4%), 32 (4.7%), and 124 patients (18.4%), respectiveely; minimally invasive adenocarcinoma was seen in 15 patients (2.2%), and variants of invasive adenocarcinoma in 45 patients (6.7%).

Prevalence and baseline characteristics of the molecular genotypes
------------------------------------------------------------------

*KRAS* mutation detection was not performed in 29 of the 675 patients because of a lack of specimens; otherwise there was sufficient tissue to undergo *EGFR* and *KRAS* mutation detection and *ALK* fusion gene assays. *EGFR* and *KRAS* mutations were detected in 312 (46.2%) and 70 (10.8%) patients, respectively. Seventy-five patients (11.1%) were *ALK* fusion-positive, and the remaining 226 (33.5%) were wild-type (WT) for *EGFR*, *ALK*, and *KRAS* (WT/WT/ WT). Genetic alterations in *ALK*, *EGFR*, and *KRAS* were mutually exclusive. However, the coexistence of *EGFR* mutations and *ALK* rearrangement was detected in 5 patients. Two samples possessed both *EGFR* and *KRAS* mutations.

Among the 312 patients with *EGFR* mutations, 132 (42.3%) had in-frame deletions in exon 19, 147 (47.1%) had point mutations in exon 21 at L858, 12 (3.8%) in exon 18, and 13 (4.2%) had in-frame insertions in exon 20. The remaining 10 (3.2%) patients exhibited multiple mutations, of whom seven patients possessed sensitive mutations in exons 19 and 21, and three patients possessed sensitive and primarily resistant mutations in the exon 20 insertion.

*ALK*-positive patients were substantially younger (55.3±9.0 years old) than patients with *EGFR* mutations (59.6±8.2 years old) and those with a WT status (59.8±7.8 years old) (*P* \< 0.05 for both). *EGFR* mutations and *ALK* rearrangements were more frequently found in women (62.8% and 57.3%, respectively), and nonsmokers (67.6% and 69.3%, respectively) (*P* \< 0.05 for both). The frequency of *ALK* rearrangement in never/light smokers was higher than in those with *EGFR* mutations, but the difference was not significant. The rate of pathological stage I disease was significantly higher among patients with *EGFR* mutations (61.2%) than in those with *ALK* rearrangements (44.0%; *P* \< 0.05). Lymph node metastasis and postoperative adjuvant therapy were more common in patients with *ALK* rearrangements (48% and 64%, respectively) than in those with *EGFR* mutations (32.7% and 48.4%, respectively) (*P* \< 0.05). No significant differences in Eastern Cooperative Oncology Group performance status score, family history of cancer, surgical technique, or tumor diameter were found among the different genotypes (all *P* \> 0.05).

The localization of primary tumors in patients harboring *EGFR* mutations and *ALK* rearrangements was as follows: Compared with EGFR-mutated tumors, *ALK*-positive tumors occurred more frequently in multiple lobes (13.3% vs 5.8%; *P*= 0.043), and were less common in the upper right lobe (14.7% vs 30.8%; *P* = 0.006).

Pathological subtype characteristics
------------------------------------

The predominant tumor subtypes in patients with *EGFR* mutations and *ALK* rearrangements patients are shown in Table [2](#T2){ref-type="table"}. *EGFR* mutations were more common than *ALK* rearrangements in patients with the acinar predominant subtype (47.4% vs 30.7%, respectively; *P* = 0.01), and the lepidic predominant subtype (23.7% vs 6.7%, respectively; *P* \< 0.05). Compared with *EGFR* mutations, *ALK* rearrangements were more frequently detected in the solid predominant subtype with mucin production (33.3% vs 11.2%, respectively) and invasive mucinous adenocarcinomas (20% vs 3.2%, respectively) (*P* \< 0.05).

Clinical outcomes of LAC patients with *EGFR* mutations and *ALK* rearrangements
--------------------------------------------------------------------------------

The median follow-up duration of all patients was 36.6 months (range, 25.0-84.3 months). As of February 1st, 2018, 546 patients (80.9%) were still alive. However, except for two missing patients, 127 (18.8%) of the 675 patients had died, of whom 112 (95.9%) died from tumor-related causes, while four (4.1%) had tumor-unrelated deaths (postoperative infection, postoperative respiratory and circulatory failure, heart disease, and accident). Causes of death were unknown in 11 patients.

To elucidate the relationship between the status of oncogenic driver mutations and clinical outcome of patients with LAC, we analyzed the DFS and OS of patients with or without mutations. Univariate analysis indicated that DFS and OS were significantly shorter in patients with a high tumor status, lymph node involvement, high TNM stage, and those with the lepidic predominant subtype and solid predominant with mucin production subtype. Additionally, *EML4-ALK*-positive patients had a significantly shorter DFS than *EGFR* mutation-positive and WT patients (both*P* \< 0.05) (Figure [1](#F1){ref-type="fig"}B). The mean OS after surgical procedures was significantly longer in *EGFR*-mutated patients (68.6 months) than WT patients (62.3 months) (*P*=0.003). No significant differences were found in patients with *ALK*-positive tumors (57.0 months) compared with *EGFR*-mutated or WT patients (both *P* \> 0.05; Figure [2](#F2){ref-type="fig"}B).

To test the prognostic value of *EGFR* mutations and *ALK* rearrangements, we performed multivariate analysis using the Cox proportional hazard model for all variables identified as significant by univariate analysis. Multivariate analyses of DFS and OS are shown in Table [3](#T3){ref-type="table"} and Table [4](#T4){ref-type="table"}. Cox\'s proportional hazard model indicated that *EGFR* status was an independent variable for predicting OS (*P*=0.003), while *ALK* rearrangements were an independent variable for predicting DFS (*P*\<0.001).

Discussions
===========

The prognostic significance of *EGFR* mutations and *ALK* rearrangements in surgically resected LAC was unclear, so this study investigated clinicopathological features and compared outcomes between patients with these two types of genetic variations. We previously studied only ALK rearrangements in surgically-resected LAC patients; these subjects partially overlapped with those in the present study. In our earlier work [@B31], we suggested that the clinical characteristics of LAC patients with *ALK* rearrangements were similar to those of *EGFR*-mutated patients, and that *ALK* rearrangements were an adverse prognostic factor. However, we did not determine the *EGFR* or *KRAS* status.

Individuals from Western countries are known to have lower rates of *EGFR* mutations and *ALK* rearrangements than Asians [@B32], [@B33]. In the present study, we observed frequencies of 46.2% and 11.1%, respectively, in resected LAC tissue. Consistent with previous studies [@B34], [@B35], patients in both groups were more likely to be younger, female, and to be never or light smokers (Table [2](#T2){ref-type="table"}). We also showed that *ALK*-positive patients exhibited characteristic clinical and pathological features compared with WT or those with *EGFR* mutations. Patients with *ALK* rearrangements were significantly younger than those with *EGFR* mutations (*P* \< 0.001), while early-stage (stage I) LAC was more common in *EGFR-*mutated patients than those with *ALK* rearrangements (*P* \< 0.05). In LAC patients with*ALK* rearrangements, the primary tumor site is more likely to simultaneously localize in multiple lobes, and less likely to be found in the upper right lobe than in those with *EGFR* mutations (Table [2](#T2){ref-type="table"}). In the absence of appropriate genetic testing, these features may aid the differentiation of *ALK* rearrangements from *EGFR* mutations which is important because *ALK*-positive lung cancer is strongly associated with resistance to EGFR TKIs [@B15], [@B21].

*ALK* rearrangements and *EGFR* mutations were previously reported to be mutually exclusive [@B15], [@B36], [@B37]. In our study, *ALK* rearrangements were more likely to occur in specimens without *EGFR* mutations (*P* \< 0.05). However, an increasing number of studies [@B37]-[@B40] showed that *ALK* rearrangements can occur concurrently with *EGFR* mutations, typically at an incidence \<1% in NSCLC. We observed concomitant *EGFR* and *ALK* alterations in 0.74% of LAC patients and 6.7% of *ALK*-positive cases. *KRAS* mutations and *ALK* rearrangements did not occur together in our cohort, and no cases exhibited all three driver gene mutations. Our results further indicate that *ALK* rearrangements and *EGFR* and *KRAS* mutations are almost mutually exclusive within a single tumor [@B33].

The significant association noted between *ALK* rearrangements and *EGFR* mutations with histological subtypes is controversial. Several reports indicated that *EGFR* mutations are frequently associated with adenocarcinoma with a lepidic growth pattern [@B41], [@B42], while the solid predominant subtype with mucin production pattern and lack of lepidic growth was shown to be more common in *ALK*-positive patients [@B2], [@B43], [@B44]. Using the 2011 IASLC/ATS/ERS international multidisciplinary classification of LAC, our study showed that most tumors with *ALK* rearrangements had a solid predominant subtype with mucin production or were invasive mucinous adenocarcinomas (*P* \< 0.05). *EGFR* mutations were more common in patients with the acinar predominant subtype and the lepidic predominant subtype (*P*\<0.05). These results differed from previous studies. For example, Zaric et al. [@B45] showed that the acinar subtype of LAC was significantly (*P* = 0.02) associated with the *EML4-ALK*- positive mutation status, while Dong et al. [@B2] reported that *EGFR* mutations were more closely associated with the acinar predominant (*P* = 0.030) and papillary predominant (*P* = 0.006) subtypes. Additionally, *ALK* rearrangements occurred more commonly in tumors of the solid predominant subtype than other subtypes (*P*= 0.002), and less commonly in the papillary predominant subtype (*P* = 0.004). Despite these reported differences, LAC histology is associated with *EGFR* mutation status, as seen by the higher frequency of *EGFR* mutations in tumors with acinar and lepidic patterns than those with a solid pattern [@B46].

Several studies have shown that *EGFR* mutations might be a prognostic predictor for patients with advanced or early NSCLC. Sonobe et al. [@B5] indicated that stage I adenocarcinoma or large cell carcinoma patients with *EGFR-*mutated tumors have a higher 5-year survival rate than those with *EGFR* WT tumors (*P* = 0.037). Similarly, Chao et al. [@B47] revealed that patients with *EGFR*-mutated tumors had significantly longer OS than those with *EGFR*-WT tumors (*P* = 0.002), while Izar et al. found that *EGFR* mutations were an independent prognostic factor in completely resected stage I NSCLC [@B48]. We observed a significantly longer mean OS after surgical procedures in *EGFR*-mutated patients than WT patients (*P* = 0.003), which is consistent with previous studies.

Yang et al. reported that *ALK* rearrangements were significantly associated with poor DFS in never-smoker patients with surgically resected LAC [@B49]. Zhou et al. also found that *ALK* rearrangements were significantly associated with poor prognosis in a stage IIIA subgroup of NSCLC patients. However, in stage IA NSCLC, *ALK*-positive patients had longer DFS than *ALK*-negative patients [@B4]. In our present study, patients with *EML4-ALK* fusions had a significantly shorter DFS than those with *EGFR* mutations or WT patients. However, there was no difference in OS. Multivariate analysis also identified *EML4-ALK* fusion as an independent factor for poor DFS (but not OS) in our study. However, Blackhall et al. [@B50] showed that *ALK* positivity was a predictor for better OS in patients with surgically resected LAC, while Kim et al. [@B46] revealed that the median OS was longer in *ALK*-positive lung cancer patients than in *EGFR*-positive or WT patients. The prognostic significance of *ALK* rearrangements in surgically resected LAC therefore remains inconclusive.

Few studies have made a prognostic comparison of *EGFR* mutations and *ALK* rearrangements in patients after surgical resection of early LAC. Kim et al. [@B46] reported a significantly longer median OS after surgical procedures in *ALK*-positive patients compared with those patients with *EGFR* mutations (*P*=0.0266). We observed a significantly worse DFS in *EML4-ALK*-positive patients compared with *EGFR*-mutated ones (*P*=0.012). However, there was no significant difference in mean OS between the two groups (*P*\>0.05, Figure [2](#F2){ref-type="fig"}).

The current study has some limitations. It was a retrospective study conducted in a single large institution. Therefore, our findings should be validated by a prospective study of a larger sample from multiple centers. Moreover, because our study reviewed patients from January 2011 to December 2015, we were unable to obtain complete prognostic information, so some 3-year and 5-year survival data are missing. Therefore, the follow-up duration needs to be extended for OS analysis. Additionally, future analysis should obtain details about treatment after tumor recurrence, which could influence the results. Nevertheless, our results are promising, and we are encouraged to confirm them in longer follow-up research and to conduct additional studies on patients with mutations in other oncogenes.

In conclusion, we demonstrated that younger patients, those with the solid predominant subtype with mucin production and invasive mucinous adenocarcinoma, a higher defined TNM stage, and lymph node metastasis were more likely to harbor *ALK* rearrangements than *EGFR* mutations in early-stage surgically resected LAC. Patients with *ALK* rearrangements had a significantly worse DFS than those with *EGFR* mutations, indicating that *ALK* rearrangements are an adverse prognostic factor, while *EGFR* mutations are associated with a better prognosis.
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:   non-small cell lung cancer

LAC
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:   anaplastic lymphoma kinase
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:   epidermal growth factor receptor
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:   kirsten rat sarcoma viral oncogene homolog
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:   disease-free survival

OS
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TKI
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:   immunohistochemistry
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TNM

:   tumor-node-metastasis
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###### 

Clinicopathologic characteristics of patients with adenocarcinoma

  Variable                            n (%)
  ----------------------------------- -----------
  **Age, years**                      
  ≥60                                 355(52.6)
  \<60                                320(47.4)
  Median                              60
  **Sex**                             
  Male                                320(47.4)
  Female                              355(52.6)
  **Smoking history^a^**              
  Never                               376(55.7)
  Smoker                              299(44.3)
  **ECOG PS**                         
  0                                   358(53.0)
  1                                   317(47.0)
  **Family history of cancer**        
  Yes                                 132(19.6)
  No                                  543(80.4)
  **Localization of primary tumor**   
  LUL                                 127(18.8)
  LLL                                 122(18.1)
  RUL                                 203(30.1)
  RML                                 55(8.1)
  RLL                                 126(18.7)
  Others^b^                           42(6.2)
  **Operating methods**               
  Open thoracotomy                    389(57.6)
  Thoracoscopy                        286(42.4)
  **Tumor size**                      
  ≥3                                  330(48.9)
  \<3                                 345(51.1)
  Median                              2.8
  **Lymph node metastasis**           
  Yes                                 229(33.9)
  No                                  446(66.9)
  **TNM Stage**                       
  I                                   380(56.3)
  II                                  73(10.8)
  III                                 222(32.9)
  **Adenocarcinoma subtype**          
  Invasive ADC^c^                     
  Lepidic                             126(18.7)
  Acinar                              283(41.9)
  Papillary                           50(7.4)
  Micropapillary                      32(4.7)
  Solid                               124(18.4)
  Variants of invasive ADC            45(6.7)
  Minimally invasive ADC              
  Nonmucinous                         9(1.3)
  Mucinous                            6(0.9)
  **Adjuvant therapy^c^**             
  Yes                                 360(53.3)
  No                                  310(45.9)
  Unknown                             5(0.8)

^a^Never smokers have smoked \<100 cigarettes in their lifetime; smokers have smoked ≥100 cigarettes.^b^Dragging in several lobes. ^c^Adjuvant therapy included chemotherapy, radiotherapy, and biotherapy.

ADC, Adenocarcinoma; RUL, right upper lobe; RML, right middle lobe; RLL, right lower lobe; LUL, left upper lobe; LLL, left lower lobe; ECOG PS, Eastern Cooperative Oncology Group performance status score; TNM, tumor-node-metastasis.

###### 

Clinical characteristics of *EGFR*/*KRAS* mutation status and *ALK* rearrangement in patients with lung adenocarcinoma

  Variable                        ALK        EGFR        KRAS       WT^a^       *p* Value^b^               
  ------------------------------- ---------- ----------- ---------- ----------- -------------- ----------- ------------
                                                                                ALK vs EGFR    ALK vs WT   EGFR vs WT
  Total evaluated                 75(11.1)   312(46.2)   70(10.8)   226(33.5)                              
  Age                                                                                                      
  Mean±SD                         55.3±9.0   59.6±8.2    60.6±7.7   59.8±7.8    \<0.001        \<0.001     0.858
  Gender                                                                                                   
  Male                            32(42.7)   116(37.2)   48(68.6)   129(57.1)   0.428          0.033       \<0.001
  Female                          43(57.3)   196(62.8)   22(31.4)   97(42.9)                               
  Smoking history                                                                                          
  Never                           52(69.3)   211(67.6)   21(30.0)   98(43.4)    0.89           \<0.001     \<0.001
  Smoker                          23(30.7)   101(32.4)   49(70.0)   128(56.6)                              
  ECOG PS score                                                                                            
  0                               47(62.7)   168(53.8)   32(45.7)   117(51.8)   0.196          0.11        0.662
  1                               28(37.3)   144(46.2)   38(54.3)   109(48.2)                              
  Family history of cancer                                                                                 
  Yes                             14(18.7)   58(18.6)    11(15.7)   50(22.1)    1              0.626       0.328
  No                              61(81.3)   254(81.4)   59(84.3)   176(77.9)                              
  Localization of primary tumor                                                                            
  LUL                             14(18.7)   60(19.2)    15(21.4)   41(18.1)    0.027          0.004       0.865
  LLL                             16(21.3)   56(17.9)    14(20.0)   40(17.7)                               
  RUL                             11(14.7)   96(30.8)    18(25.7)   78(34.5)                               
  RML                             6(8.0)     27(8.7)     6(8.6)     16(7.1)                                
  RLL                             18(24.0)   55(17.6)    12(17.1)   42(18.6)                               
  Others                          10(13.3)   18(5.8)     5(7.1)     9(4.0)                                 
  Operating technique                                                                                      
  Open thoracotomy                45(60.0)   164(52.6)   52(74.3)   131(58.0)   0.302          0.788       0.22
  Thoracoscopy                    30(40.0)   148(47.4)   18(25.7)   95(42.0)                               
  Tumor diameter(cm)                                                                                       
  Mean ± SD                       3.1±1.8    2.8±1.3     3.5±1.9    3.3±2.0     0.666          0.391       0.054
  Tumor stage                                                                                              
  T1                              43(57.3)   211(67.6)   38(54.3)   133(58.8)   0.153          0.815       0.111
  T2                              17(22.7)   67(21.5)    21(30.0)   56(24.8)                               
  T3                              6(8.0)     13(17.3)    6(8.6)     18(8.0)                                
  T4                              9(12.0)    21(67.3)    5(7.1)     19(8.4)                                
  Lymph node metastasis                                                                                    
  Yes                             36(48.0)   102(32.7)   16(22.9)   79(35.0)    0.016          0.055       0.644
  No                              39(52.0)   210(67.3)   54(77.1)   147(65.0)                              
  TNM Stage                                                                                                
  I                               33(44.0)   191(61.2)   40(57.1)   120(53.1)   0.009^c^       0.185^c^    0.064^c^
  II                              13(17.3)   20(6.4)     12(17.1)   30(13.3)                               
  III                             29(38.7)   101(32.4)   18(25.7)   76(33.6)                               
  Adenocarcinoma subtype                                                                                   
  Lepidic predominant             5(6.7)     74(23.7)    4(5.7)     44(19.5)    \<0.001        \<0.001     0.058
  Acinar predominant              23(30.7)   148(47.4)   26(37.1)   88(38.9)                               
  Papillary predominant           5(6.7)     24(7.7)     4(5.7)     18(8.0)                                
  Micropapillary predominant      2(2.7)     15(4.8)     3(4.3)     12(5.3)                                
  Solid predominant               25(33.3)   35(11.2)    22(31.4)   44(19.5)                               
  Invasive mucinous ADC           15(20.0)   10(3.2)     7(10.0)    13(5.8)                                
  Others^d^                       0          6(1.9)      4(5.7)     7(3.1)                                 
  Adjuvant therapy                                                                                         
  Yes                             48(64.0)   151(48.4)   35(50.0)   126(55.8)   0.01           0.084       0.238
  No                              25(33.3)   159(51.0)   35(50.0)   99(43.8)                               
  Unknown                         2(2.7)     2(0.6)      0          1(0.4)                                 

^a^*ALK*/*EGFR*/*KRAS*-negative patients. ^b^Age (years) and tumor diameter (cm) analysis used the Wilcoxon rank sum test; others used the Fisher\'s exact test. ^c^ p-value was calculated by comparing patients with TNM stage I vs. patients with stage II and III. ^d^Enteric ADC, Colloid ADC and Minimally invasive ADC.

ALK, anaplastic lymphoma kinase; EGFR, epidermal growth factor receptor; KRAS, Kirsten rat sarcoma viral oncogene homolog; WT, wild type. ADC, Adenocarcinoma; RUL, right upper lobe; RML, right middle lobe; RLL, right lower lobe; LUL, left upper lobe; LLL, left lower lobe; ECOG PS, Eastern Cooperative Oncology Group performance status score; TNM, tumor-node-metastasis.

###### 

Uni- and multivariate analyses of prognostic factors for disease-free survival

  ----------------------------------------------------------------------------------------------------------------------------
  Variable                No. of\       Univariate analysis             Multivariate analysis                        
                          recurrences                                                                                
  ----------------------- ------------- --------------------- --------- ----------------------- -------------------- ---------
  Age                                                                                                                

  \<60                    132           1                     0.283                                                  

  ≥60                     123           1.144(0.895-1.463)                                                           

  Gender                                                                                                             

  Female                  128           1                     0.724                                                  

  Male                    127           1.045(0.819-1.334)                                                           

  ECOG PS                                                                                                            

  0                       110           1                     0.046                             1                    0.042

  1                       145           1.286(1.004-1.647)                                      1.299(1.009-1.671)   

  Operating technique                                                                                                

  Thoracoscopy            81            1                     0.731                                                  

  Open thoracotomy        174           1.046(0.809-1.354)                                                           

  T stage                                                                                                            

  T1+2                    204           1                     0.007                                                  

  T3+4                    51            1.524(1.121-2.072)                                                           

  Lymph node metastasis                                                                                              

  No                      122           1                     0.019                                                  

  Yes                     134           1.344(1.050-1.720)                                                           

  pTNM stage                                                                                                         

  I+II                    110           1                     0.001                             1                    0.001

  III                     145           1.530(1.190-1.967)                                      1.598(1.240-2.059    

  Lepidic subtype                                                                                                    

  \-                      218           1                     0.257                                                  

  \+                      37            0.817(0.576-1.159)                                                           

  Solid subtype                                                                                                      

  \-                      198           1                     0.002                             1                    0.016

  \+                      62            1.579(1.183-2.107)                                      1.438(1.071-1.930)   

  EGFR                                                                                                               

  \+                      108           1                     0.476                                                  

  \-                      147           1.094(0.855-1.399)                                                           

  ALK                                                                                                                

  \-                      221           1                     \<0.001                           1                    \<0.001

  \+                      34            1.996(1.374-2.900)                                      1.974(1.347-2.893)   
  ----------------------------------------------------------------------------------------------------------------------------

^a^p-values were calculated using the Cox-proportional hazard model.

ALK, anaplastic lymphoma kinase; EGFR, epidermal growth factor receptor; ECOG PS, Eastern Cooperative Oncology Group performance status score; TNM, tumor-node-metastasis; HR, hazard ratio; CI, confidence interval.

###### 

Uni- and multivariate analyses of prognostic factors for overall survival

  ----------------------------------------------------------------------------------------------------------------------------
  Variable                    No. of\   Univariate analysis             Multivariate analysis                        
                              deaths                                                                                 
  --------------------------- --------- --------------------- --------- ----------------------- -------------------- ---------
  **Age**                                                                                                            

  \<60                        57        1                     0.753                                                  

  ≥60                         59        0.943(0.655-1.358)                                                           

  **Gender**                                                                                                         

  Female                      50        1                     0.023                                                  

  Male                        66        1.532(1.061-2.213)                                                           

  **ECOG PS**                                                                                                        

  0                           44        1                     0.034                                                  

  1                           72        1.507(1.033-2.201)                                                           

  **Operating technique**                                                                                            

  Thoracoscopy                32        1                     0.008                                                  

  Open thoracotomy            84        1.716(1.149-2.563)                                                           

  **T stage**                                                                                                        

  1+2                         86        0.417(0.275-0.633)    \<0.001                                                

  3+4                         30        1                                                                            

  **Lymph node metastasis**                                                                                          

  No                          45        0.361(0.250-0.522)    \<0.001                                                

  Yes                         71        1                                                                            

  **pTNM stage**                                                                                                     

  I+II                        44        0.266(0.183-0.388)    \<0.001                           0.274(0.188-0.400)   \<0.001

  III                         72        1                                                       1                    

  **Lepidic subtype**                                                                                                

  \-                          104       1                     0.014                                                  

  \+                          12        0.470(0.258-0.856)                                                           

  **Solid subtype**                                                                                                  

  \-                          74        1                     \<0.001                           1                    \<0.001

  \+                          42        3.169(2.164-4.640)                                      2.580(1.753-3.798)   

  **EGFR**                                                                                                           

  \+                          35        1                     0.003                             1                    0.003

  \-                          81        1.799(1.216-2.660)                                      1.814(1.223-2.693)   

  **ALK fusion**                                                                                                     

  \+                          14        1                     0.937                                                  

  \-                          102       0.977(0.557-1.717)                                                           
  ----------------------------------------------------------------------------------------------------------------------------

^a^p-values were calculated using the Cox-proportional hazard model.

ALK, anaplastic lymphoma kinase; EGFR, epidermal growth factor receptor; ECOG PS, Eastern Cooperative Oncology Group performance status score; TNM, tumor-node-metastasis; HR, hazard ratio; CI, confidence interval.
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